Evidence map›Paper›PMID 40548749›Full record

ArticlemBio2025

Evolutionary dynamics of heparan sulfate utilization by SARS-CoV-2.

Shuhei Higuchi, Yafei Liu, Jun Shimizu, Chikako Ono, Yumi Itoh, Wataru Nakai, Hui Jin, Kazuki Kishida, Kazuo Takayama, Toru Okamoto and 5 more

Abstract read
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shuhei HiguchiCenter for Advanced Modalities and DDS, Osaka University, Suita, Osaka, Japan.ORCID 0009-0009-6107-6440
Yafei LiuCenter for Advanced Modalities and DDS, Osaka University, Suita, Osaka, Japan.
Jun ShimizuMiCAN Technologies Inc., Kyoto, Japan.ORCID 0000-0002-6461-4648
Chikako OnoCenter for Infectious Disease Education and Research, Osaka University, Suita, Osaka, Japan.
Yumi ItohDepartment of Microbiology, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan.
Wataru NakaiDepartment of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Hui JinDepartment of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Kazuki KishidaDepartment of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Kazuo TakayamaCenter for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.ORCID 0000-0002-1132-2457
Toru OkamotoDepartment of Microbiology, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan.
Yoshiko MurakamiLaboratory of Immunoglycobiology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Taroh KinoshitaCenter for Infectious Disease Education and Research, Osaka University, Suita, Osaka, Japan.
Yoshiharu MatsuuraCenter for Advanced Modalities and DDS, Osaka University, Suita, Osaka, Japan.ORCID 0000-0001-9091-8285
Tatsuo ShiodaCenter for Infectious Disease Education and Research, Osaka University, Suita, Osaka, Japan.
Hisashi AraseCenter for Advanced Modalities and DDS, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-1153-3166

Funding

Japan Agency for Medical Research and Development 223fa627002hJapan Agency for Medical Research and Development 25ek0410124hJapan Agency for Medical Research and Development 25gm1810006hJapan Science and Technology Agency JPMJSP2138Japan Society for the Promotion of Science 22H04989
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants have acquired enhanced infectivity compared to earlier variants. To elucidate the underlying molecular mechanisms, we conducted CRISPR library screening to identify cell surface molecules that interact with the Omicron spike protein. Our findings revealed a significantly higher affinity between the Omicron spike and cell surface heparan sulfate compared to the wild-type spike. This increased binding affinity enables Omicron variants to infect cells expressing low levels of ACE2, which are minimally infected by the wild-type virus. Mutational analysis of heparan sulfate binding sites on the Omicron spike protein, coupled with electrostatic potential mapping, suggested that the accumulation of positively charged mutations has contributed to the enhanced heparan sulfate binding. Comparative analysis of heparan sulfate binding among Omicron subvariants-including BA.1, BA.2, BA.4, BA.5, XBB.1, and BA.2.86-revealed that most are likely to bind efficiently to heparan sulfate, but potential heparan sulfate binding sites of the spike protein have shifted from the early Omicron variants to more recent ones. Furthermore, we discovered that cell surface heparan sulfate proteoglycans are cleaved by TMPRSS2, a protease essential for wild-type SARS-CoV-2 infection. These findings suggest that SARS-CoV-2 is evolving to enhance its infectivity by optimizing its interaction with cell surface heparan sulfate.IMPORTANCEThe Omicron variant has evolved to become highly infectious by acquiring numerous mutations. Understanding the impact of these mutations can provide valuable insights into the drivers of viral evolution and aid in the development of improved viral surveillance and vaccines. Our study demonstrates that the Omicron variants contain mutations that enhance their ability to bind to heparan sulfate. Highly infectious human viruses often utilize heparan sulfate for infection, suggesting that heparan sulfate likely plays a crucial role in viral adaptation to human hosts. Furthermore, we found that cell surface heparan sulfate proteoglycans are sensitive to TMPRSS2, while most other cell surface proteins are resistant to TMPRSS2. Given that TMPRSS2 is known to enhance the infectivity of earlier severe acute respiratory syndrome coronavirus 2 variants but cleaves heparan sulfate proteoglycans, it is probable that the high heparan sulfate binding acquired by the Omicron variant contributes to its decreased infectivity against TMPRSS2-expressing cells compared to earlier variants.

Indexed as

COVID-19Heparan SulfateSARS-CoV-2Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Binding SitesEvolution, MolecularHEK293 CellsHumansMutationProtein BindingACE2 protein, humanAngiotensin-Converting Enzyme 2Heparan SulfateSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2heparan sulfateOmicronSARS-CoV-2TMPRSS2

Identifiers

PMID40548749
PMCPMC12345153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.